Evaluating Key Challenges and Advancements in Prostate Cancer Care
In Partnership With
Alan H. Bryce, MD, discusses ongoing research in radioligand therapies.
Among the 4 major tumor locations—breast, lung, colon, and prostate—biological genotypes have yet to be established for prostate cancer, explains Alan H. Bryce, MD, chief clinical officer and professor of Medical Oncology and Developmental Therapeutics at City of Hope in Phoenix, Arizona, in this video. Clinical trial designs are being developed to better understand prostate cancer biology and establish a treatment paradigm.
Bryce notes that different genotypes of breast cancer are treated distinctly, leading to better efficacy and treatment optimization. However, achieving this level of precision remains an ongoing challenge in prostate cancer management. He highlights a recent breakthrough with capivasertib (Truqap) in combination therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer, as announced in a recent press release.1
Another major challenge that Bryce addresses is the advancement of non-castrating treatment approaches, which is a key concern for patients with prostate cancer. He questions whether effective treatment can be achieved without suppressing testosterone.
“With all of these things being evaluated, can we ask the question: ‘Can we do this without suppressing testosterone?’ I think that is something actively being worked on. On one hand, we have bipolar antigen therapy, which is promising, but it is still not non-castrating. So, we aim to push that advancement further.”
Bryce also discusses ongoing research in radioligand therapies (RLT), recognizing RLT as a platform for innovation and other potential for targeted therapies.
“There are other cell surface targets beyond prostate-specific membrane antigen that can be explored, and other isotopes besides lutetium that can be utilized” Bryce says.
He believes that in the future, there will be a library of RLTs available for prostate cancer management, expanding treatment options and personalization for patients.
References
Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 phase III trial. News release. AstraZeneca. November 25, 2024. Accessed March 21, 2025. https://tinyurl.com/5a6bje9m
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
